CN115349635A - 对孕产妇施用维生素b6预防后代发胖、超重或肥胖的增加 - Google Patents
对孕产妇施用维生素b6预防后代发胖、超重或肥胖的增加 Download PDFInfo
- Publication number
- CN115349635A CN115349635A CN202210975211.1A CN202210975211A CN115349635A CN 115349635 A CN115349635 A CN 115349635A CN 202210975211 A CN202210975211 A CN 202210975211A CN 115349635 A CN115349635 A CN 115349635A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- obesity
- accordance
- offspring
- overweight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 title claims abstract description 174
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 title claims abstract description 87
- 235000019158 vitamin B6 Nutrition 0.000 title claims abstract description 87
- 239000011726 vitamin B6 Substances 0.000 title claims abstract description 87
- 229940011671 vitamin b6 Drugs 0.000 title claims abstract description 87
- 235000020824 obesity Nutrition 0.000 title claims abstract description 40
- 208000008589 Obesity Diseases 0.000 title claims abstract description 39
- 206010033307 Overweight Diseases 0.000 title claims abstract description 33
- 230000035935 pregnancy Effects 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 230000008774 maternal effect Effects 0.000 claims abstract description 26
- 238000009825 accumulation Methods 0.000 claims abstract description 22
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 20
- 235000016709 nutrition Nutrition 0.000 claims abstract description 19
- 230000006651 lactation Effects 0.000 claims abstract description 17
- 230000002265 prevention Effects 0.000 claims abstract description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 229960000304 folic acid Drugs 0.000 claims description 4
- 235000019152 folic acid Nutrition 0.000 claims description 4
- 239000011724 folic acid Substances 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 235000001465 calcium Nutrition 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 235000000832 Ayote Nutrition 0.000 claims description 2
- 235000010523 Cicer arietinum Nutrition 0.000 claims description 2
- 244000045195 Cicer arietinum Species 0.000 claims description 2
- 241000723382 Corylus Species 0.000 claims description 2
- 235000007466 Corylus avellana Nutrition 0.000 claims description 2
- 241000219122 Cucurbita Species 0.000 claims description 2
- 235000009854 Cucurbita moschata Nutrition 0.000 claims description 2
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 240000006711 Pistacia vera Species 0.000 claims description 2
- 240000004713 Pisum sativum Species 0.000 claims description 2
- 235000010582 Pisum sativum Nutrition 0.000 claims description 2
- 244000000231 Sesamum indicum Species 0.000 claims description 2
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 2
- 244000061456 Solanum tuberosum Species 0.000 claims description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 235000021336 beef liver Nutrition 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000021329 brown rice Nutrition 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims description 2
- 235000015143 herbs and spices Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 235000014571 nuts Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000020233 pistachio Nutrition 0.000 claims description 2
- 235000015136 pumpkin Nutrition 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000020238 sunflower seed Nutrition 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 210000001835 viscera Anatomy 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 210000001015 abdomen Anatomy 0.000 claims 1
- 230000035764 nutrition Effects 0.000 abstract description 9
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 20
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 19
- 229960001327 pyridoxal phosphate Drugs 0.000 description 19
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 208000007683 Pediatric Obesity Diseases 0.000 description 8
- 208000003056 Vitamin B6 deficiency Diseases 0.000 description 8
- 238000003908 quality control method Methods 0.000 description 8
- 239000011785 micronutrient Substances 0.000 description 7
- 235000013369 micronutrients Nutrition 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000018823 dietary intake Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 235000020820 vitamin B6 status Nutrition 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000001596 intra-abdominal fat Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000008376 long-term health Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000020802 micronutrient deficiency Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000006180 nutrition needs Nutrition 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000001121 post-column derivatisation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- XGEYXJDOVMEJNG-HTFDPZBKSA-N Marein Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 XGEYXJDOVMEJNG-HTFDPZBKSA-N 0.000 description 1
- XGEYXJDOVMEJNG-CMWLGVBASA-N Marein Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)O)=CC=C1C(=O)C=CC1=CC=C(O)C(O)=C1 XGEYXJDOVMEJNG-CMWLGVBASA-N 0.000 description 1
- 208000025972 Maternal Obesity Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010386 affect regulation Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009985 maternal smoking Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- -1 soy lecithin) Chemical compound 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000020812 vitamin status Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/7052—Vitamin B6
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明整体涉及婴幼儿超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的早期预防。例如，本发明涉及通过为希望怀孕和/或孕期和/或哺乳期的妇女提供适当的营养来预防婴幼儿超重、肥胖、过量脂肪积聚和/或相关代谢紊乱。本发明的实施方案涉及用于预防后代超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的维生素B6的用途，其中将所述维生素B6施用于希望怀孕的妇女，以及/或者孕期和/或哺乳期的母亲，本发明的实施方案还涉及可用于上述目的的孕产妇食物组合物。
Description
本申请是中国专利申请201580003950.2的分案申请，原申请的申请日是2015年1月9日，发明名称是“对孕产妇施用维生素B6预防后代发胖、超重或肥胖的增加”。
本发明整体涉及婴幼儿超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的早期预防。例如，本发明涉及通过在孕前、孕期和/或哺乳期施用适当的孕产妇营养来预防婴幼儿超重、肥胖、过量脂肪积聚和/或相关代谢紊乱。本发明的实施方案涉及用于预防后代超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的维生素B6，其中将所述维生素B6施用于孕前、孕期和/或哺乳期的母亲，本发明的实施方案还涉及可用于上述目的的孕产妇食物组合物。
背景技术
越来越多的科学证据显示，产前和产后的早期营养和其他环境因素会影响长期健康和良好状态的调控，并且可引起慢性疾病发展的风险。有几项研究表明，在生育期饮食摄入发生变化或对各种大量和微量营养素加以控制，可影响几种生理过程，例如生长、代谢、食欲、心血管功能等(Koletzko B et al(2011)Am J Nutr 94(s):2036-43S(Koletzko B等人，2011年，《美国营养学杂志》，第94期增刊，第2036-2043页))。因此，妇女在孕前和孕期的营养状态(营养物质储备和饮食摄入)与优化新生儿和儿童健康结果相关。据信孕产妇营养会影响营养物质对发育中的胎儿的有效性和供应，这些营养物质是关键发育过程中所需的。
儿童期超重和肥胖是许多国家(包括中等收入和低收入国家)面临的主要公共健康问题，近三十年的报告显示超重率和肥胖率日益增加。2008年，英国2至15岁儿童中就有约30％的儿童超重或肥胖。有证据表明，儿童5岁时的体重是儿童未来健康和良好状态的一个良好指标(Gardner et al(2009)Pediatrics 123:e67-73(Gardner等人，2009年，《儿科学》，第123卷，第e67-73页))。相关研究表明，儿童期肥胖会增加成人期患上肥胖和其他非常不利的慢性病症(例如心血管疾病、2型糖尿病、肝并发症、肾并发症和肌肉骨骼并发症等)的风险。有力证据表明，肥胖一旦形成，将很难通过干预逆转，肥胖将会一直持续到成人期(Waters E et al.(2011)Cochrane Database of Systematic Reviews 12(Waters E等人，2011年，《Cochrane系统评价数据库12》))，这凸显了儿童期肥胖预防工作的重要性。
一些可能的早期决定性因素(包括孕产妇肥胖和糖尿病、妊娠期过量增重、孕产妇吸烟、婴儿快速生长)与在以后的生活中发生超重和肥胖具有明显的相关性(Monasta L etal.(2010)Obesity Reviews.11:695-708(Monasta L等人，2010年，《肥胖综述》，第11卷，第695-708页))。虽然这种相关性对于这些因素中的每个因素而言不大，但如果某一小风险因素在人群中高度流行，那么当这些因素作用于该归因风险时，就可产生很大的作用。而且有些可能的决定性因素可能变得比其他因素更为重要，因为这些决定性因素更易于通过实施有效干预得以解决。
缺乏微量营养素对胎儿组织和器官具有深刻且通常持久的影响，即使母体并未表现缺乏这些微量营养素的临床征兆(Ashworth CJ et al(2001)122:527-35(Ashworth CJ等人，2001年，第122卷，第527-535页))。生活在资源匮乏环境中的生育期妇女普遍存在多种微量营养素的摄入不足(Torhem LE et al.(2010)J.Nutr.140:2051S–58S(Torhem LE等人，2010年，《营养学杂志》，第140卷增刊，第2051-2058页))，而且在一些环境中，由于不良饮食导致的与超重和肥胖相关的营养不良也开始受到关注。
本发明人调查了妇女中的微量营养素缺乏情况，以鉴定可用在产前和产后早期营养中来调控长期健康和良好状态的微量营养素，尤其是对降低慢性病(例如超重、肥胖和相关代谢紊乱(如糖尿病)、心血管疾病和高血压)发展风险有积极影响的微量营养素。
本说明书中对现有技术文献的任何提及不被视为承认此类现有技术为众所周知的技术或构成本领域普遍常识的一部分。
因此，希望为本领域提供一种解决方案，所述解决方案可以尽早在生命早期降低发展超重、肥胖、过量脂肪积聚和/或相关疾病的可能性。
本发明的一个目的是提高现有技术水平，尤其是提供一种克服至少一些当前技术水平的缺点并满足上述需求的解决方案，或至少提供一种有用的替代方案。
发明内容：
本发明涉及维生素B6用于预防后代超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的用途。将所述维生素B6以多种形式施用于希望怀孕的妇女以及/或者孕期和/或哺乳期的母亲。
具体实施方式
本发明人惊奇地发现，他们可通过独立权利要求的主题实现上述目的。从属权利要求进一步拓展本发明的构想。
本发明人调查了表观遗传学作为早期营养效应的介体和标志在人类儿童期身体组成上的作用，还调查了人在以后的生活中发展肥胖和胰岛素抗性相关疾病的风险。本发明人在多组研究中进行了深入和详细的分析，他们惊奇地发现，孕妇缺乏维生素B6会导致其后代发展超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的可能性增加。
因此，本发明部分地涉及用于预防后代超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的维生素B6的用途。
本发明还涉及维生素B6用于制备预防后代超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的组合物的用途。所述用途可以是非治疗性用途。
本发明还涉及用于降低后代发展超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的可能性的维生素B6的用途。
作为另一种选择，根据本文所述的本发明的任一实施方案，维生素B6或包含维生素B6的组合物用于预防或降低发展超重、肥胖、相关代谢紊乱和/或过量脂肪积聚的可能性。
可将所述维生素B6例如施用于孕前、孕期和/或哺乳期的母亲。
维生素B6补充剂对维生素B6水平较低和/或维生素B6摄入不足的母亲特别有效。
如果摄入的维生素B6低于建议饮食摄取量(RDA)，则认为维生素B6摄入不足。RDA是指被认为足以满足每个生活阶段和每个性别群体中97.5％的健康个体的需求的每日饮食营养物质摄入水平。根据估计平均需要量(EAR)计算RDA，其中EAR基于科学文献综述预计可满足某一年龄群体中50％的个体的需要。
例如，如果孕妇每天摄入的维生素B6低于1.9mg，则可认为维生素B6摄入不足。
目前，本领域通过在孕期使用维生素B6补充剂来治疗或预防恶心和/或呕吐。
“超重”被定义为成人的BMI介于25和30之间。
“身体质量指数”或“BMI”是指体重(千克)除以身高(米)的平方所得的比值。
“肥胖症”是指储存在动物(尤其是人和其他哺乳动物)脂肪组织中的天然能量储备增至与某些健康状况或死亡率上升有关的程度的一种病症。“肥胖”被定义为成人的BMI大于30。
就儿童来说，在BMI与年龄增长(女孩或男孩)关系的图表上绘制BMI，从而获得百分位排序。百分位是评估儿童个体的体型和生长模式最常用的指标。百分位指示了儿童BMI在相同性别和年龄的儿童中的相对位置。如果儿童BMI位于第85百分位和第95百分位之间，则认为该儿童超重。如果儿童BMI位于第95百分位或第95百分位以上，则认为该儿童肥胖。
与超重、肥胖和/或过量脂肪积聚有关的代谢紊乱是相似的，并且是技术人员熟知的。例如，这些疾病包括心血管疾病，如冠心病、胰岛素抗性、2型糖尿病、高血压、睡眠呼吸暂停、呼吸道疾病和/或血脂异常；而且还包括某些癌症(如子宫内膜癌、乳腺癌和/或结肠癌)、中风、肝脏和胆囊疾病、骨关节炎和/或妇科疾病。
由于维生素B6可施用于孕期的孕妇和/或哺乳期的母亲，因此可以(例如)孕产妇食物组合物的形式被施用。
妇女在孕期和哺乳期的营养物质需求不断增加。如果增加的营养物质需求得到满足，那么可保护孕产妇和婴儿的健康。哺乳期要求孕产妇储备需要建立和补充的能量、蛋白质和其他营养物质。
孕产妇食物组合物是被设计用于帮助满足孕期和哺乳期妇女的特定营养需求的食物组合物。
例如，此类孕产妇食物组合物可包含蛋白质源、铁源、碘源、维生素A源和/或叶酸源。
孕产妇食物组合物可具有任何被母亲接受作为其饮食一部分或作为营养补充剂的形式。
例如，孕产妇食物组合物可选自粉状营养组合物(在奶或水中重构)、营养配方食品、基于谷类的产品、饮料、食品棒、营养补充剂、营养品、酸奶、乳衍生的产品、食物喷洒物(food sprinkler)、丸剂或片剂。
目前，特别被消费者广泛接受的是在奶或水中重构的粉状营养组合物。
另外，(例如)片剂形式的营养补充剂也被广泛接受。补充剂提供了选定的营养物质，但其在受试对象的整体营养需求中的占比不显著，并且/或者其在受试对象的每日能量需求中的占比不超过0.1％、1％、5％、10％或20％。
维生素B6可以任何能有效实现本发明目的的量来使用。技术人员将能够确定合适的剂量。通常，剂量将取决于母亲的年龄、体型、健康状态、生活方式和基因遗传。
在本发明的预防应用中，维生素B6的施用量足以至少部分地降低后代发展超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的风险。这样的量被定义为“预防有效剂量”。因此，维生素B6可以预防有效剂量来施用。
例如，维生素B6以对应于0.19至60mg维生素B6/天(例如，1至40.0mg维生素B6/天)的量来施用。
针对本发明的目的，优选的是定期施用维生素B6，例如一天两次、一天一次、每两天一次或每周一次。
可将维生素B6作为持续释放制剂来提供。如果是这样，使用维生素B6的频率可降低，同时身体仍能持续获得足够的维生素B6供应。
例如，可将维生素B6在孕前、部分或整个孕期和/或母乳喂养期间(哺乳期)来施用。在一个实施方案中，可将维生素B6在孕期和/或哺乳期来施用。
在一个实施方案中，本发明的组合物在孕前被施用，例如在孕前或准备怀孕前1、2或4个月被施用。
随着怀孕中三个月(尤其是怀孕末三个月)的营养需求不断增加，可能优选的是在怀孕末三个月或在怀孕中三个月和末三个月定期施用维生素B6。
例如，可每天施用维生素B6。孕期和/或哺乳期定期施用维生素B6可持续至少4、至少8、至少12、至少16、至少20、至少24、至少28、至少32或至少36个连续周。
维生素B6可以纯净物形式来使用，也可作为天然维生素B6源或其提取物来使用。
可使用高度纯化或合成的维生素B6。优选的是维生素B6由天然源提供，或维生素B6作为天然源来提供。
例如，维生素B6可由天然源提供，所述天然源为例如鱼类；器官肉如牛肝；肉类；蛋类；糙米和小麦；土豆；富含淀粉的蔬菜如鹰嘴豆、豌豆、豆类、南瓜；水果；干燥的药草和香料；坚果，如开心果和榛子；种子(如葵花籽或芝麻籽)，或上述物质的提取物和/或组合物。
维生素B6可用作单一活性成分。
还可将维生素B6与一种或多种其他化合物共同施用，如果将这些化合物施用于孕前、孕期和/或哺乳期的母亲，这些化合物具有降低后代发展超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的风险的活性。
例如，维生素B6可与维生素D(例如，维生素D3)组合施用。
组合施用维生素B6和维生素D可能特别有利，因为与单独施用维生素B6或维生素D相比，这可提高维生素的效果。
根据本发明，维生素B6可用于预防后代在以后的生活中发生超重、肥胖、过量脂肪积聚和/或相关代谢紊乱。
“在以后的生活中”包括儿童期和成人期。例如，“在以后的生活中”可指儿童期，例如至少3岁，例如至少4岁或至少6岁。
本发明人发现，本发明的主题尤其允许通过降低和/或避免后代体脂量(例如腹部和/或内脏的脂肪量)过量堆积来预防超重和/或肥胖。
这是非常有利的，因为腹部脂肪尤其与心血管疾病和其他代谢疾病和血管疾病(例如，2型糖尿病)紧密相关。内脏脂肪(又称腹内脂肪)位于腹腔内、内部器官和躯干之间，而且与2型糖尿病紧密相关。
还可能优选的是，根据本发明将维生素B6施用于其孩子尤其存在发展超重、肥胖、过量脂肪积聚和/或相关代谢紊乱的风险的母亲和/或孕妇。
形成本发明的研究表明，这些母亲和/或孕妇可能是(例如)多次生育、超重和/或肥胖的母亲，和/或患有代谢综合征的母亲。
本发明还涉及可用于本发明目的的孕产妇食物组合物。
因此，本发明涉及一种孕产妇食物组合物，其中所述孕产妇食物组合物是粉状营养配方食品，其包含蛋白质源、碳水化合物源、脂质源、卵磷脂(如大豆卵磷脂)、增量剂和0.27-27mg维生素B6/100g干重。
蛋白质源可以是奶粉或脱脂奶粉。蔗糖和/或麦芽糖糊精可用作碳水化合物源。脂质源可以是植物油。还可添加维生素和矿物质。例如，可根据政府机构(如USRDA)的建议添加维生素和矿物质。例如，日剂量单位的组合物可包含给定范围内的以下微量营养素中的一种或多种：100至2500mg钙、35至350mg镁、70至3500mg磷、2.7至45mg铁、1.1至40mg锌、0.1至10mg铜、22至1,100μg碘、6至400μg硒、77至3000μg维生素A或视黄醇活性当量(RAE)、8.5至850mg维生素C、0.14至14mg维生素B1、0.14至14mg维生素B2、1.8至35mg烟酸、0.26至26μg维生素B12、60至1000μg叶酸、3至300μg生物素、1.5至100μg维生素D、1.9至109μg维生素E。
作为另一种选择或除此之外，制剂还可包含葡萄糖浆、乳脂、鱼油、柠檬酸镁、胆碱盐和胆碱酯、益生菌培养物、益生元纤维和/或抗坏血酸棕榈酸酯。
例如，可添加风味物化合物(例如，可可粉或蜂蜜)来提供不同口味。
组合物还可包含益生菌、叶酸、钙、铁、ARA、EPA和/或DHA。
本领域的技术人员将理解，在不脱离本文所公开的本发明范围的前提下，他们可以自由地组合本文所述的本发明的所有特征。具体地讲，针对本发明的用途描述的特征可适用于本发明的孕产妇食物组合物，反之亦然。
尽管以举例的方式对本发明进行了描述，但应当理解，在不脱离权利要求书中所限定的本发明范围的前提下，可作出变型和修改。此外，对于具体的特征如果存在已知的等同物，则应这些等同物引入本说明书中，如同在本说明书中明确提到这些等同物。参见附图和非限制性实施例后，本发明的更多优点和特征将变得显而易见。
附图说明：
图1示出了怀孕后期缺乏维生素B6(血清水平<20nmol)的妇女生育的后代在4岁时具有更严重的儿童肥胖，其中肥胖利用双能X线吸收测量法(DXA)测定。在小图a)中，后代中较高的脂肪量值(克)与孕产妇缺乏维生素B6显著相关，在b)中观察到脂肪量百分比的趋势。
图2示出了怀孕后期缺乏维生素B6(血清水平<20nmol)的妇女生育的后代在6岁时具有更严重的儿童肥胖，其中利用DXA测定肥胖。小图a)中后代较高的脂肪量值(克)和图b)中后代较高的脂肪量百分比均与孕产妇缺乏维生素B6显著相关。
实施例：
实验和临床研究表明，孕产妇在孕期的营养状态对后代在以后的生活中的结果具有终身影响。在我们的研究中，我们试图鉴定出临床学和营养学所定义的组，这些组的后代在以后的生活中出现未达标的身体组成的风险增加。
研究设计：
分析中包括的母婴群体：
选择了英国南安普敦妇女调查(Southampton Women’s Survey,SWS)中的501对母婴，采集怀孕后期孕产妇血清试样，并利用DXA测定其后代在4岁和6岁时的身体组成。所分析的SWS受试对象的特征概要如下：
1)测量孕产妇血清样品中的维生素B6(PLP)。
利用具有柱后衍生和荧光检测功能的反相高效液相色谱(HPLC)法，测定5-磷酸吡哆醛(PLP)。(Rybak ME,Pfeiffer CM.Clinical analysis of vitamin B6:Determinationof pyridoxal 50-phosphate and 4-pyridoxic acid in human serum by reversed-phase high-performance liquid chromatography with chlorite post columnderivatization.Analytical Biochemistry 2004；333:336-344(Rybak ME和PfeifferCM，“维生素B6的临床分析：利用具有亚氯酸盐柱后衍生功能的反相高效液相色谱法测定人血清中的5-磷酸吡哆醛和4-吡哆酸”，《分析生物化学》，2004年，第333卷，第336-344页))。由于没有用于维生素B6 HPLC方法的外部质量方案，因此通过内部程序实现质量控制(QC)。通过向人血浆中加入PLP水溶液，制得QC物质。最终QC浓度被设计成与典型的中间范围的人类样品和预先提供的CDC“中间台(mid bench)”质量控制品相匹配。对QC物质进行加标，使得额外的含水量仅占总介质的0.02％。每次分析运行执行两次QC物质分析。如果平均回收率在标称值的95％至105％范围之外，则对该运行的分析结果进行相应纠正。质量控制中所获得的PLP值与预期值具有良好的一致性，表明这种方法的准确度较高。
如果有少数样品在初始分析中所得的浓度值位于校准范围之外，则对这几个样品重复进行分析。有甚至更少样品的浓度被报告为低于最低的校准标准，因为在极大程度上，不可能对这些样品进行再次分析。这种方法意味着，一些被再次分析的样品被报告为其浓度值远远低于底标准(bottom standard)，同时有些样品被呈现为低于值(less thanvalue)。在统计分析中，我们为具有低于底标准的值的那些样品(3个受试对象)分配了介于0与校准范围底值之间的中间值。一个受试对象没有PLP峰，因此其PLP浓度被设为“0”。
通常利用血浆PLP水平来评估维生素B6状态。由于血浆PLP以PLP-白蛋白复合物的形式从肝脏中运出，因此认为血浆PLP可反映肝脏B6的水平和储备(Lumeng L,Ryan MP,LiTK.Validation of the diagnostic value of plasma pyridoxal 50-phosphatemeasurements in vitamin B6 nutrition of the rat.J Nutr 1978；108:545-553(Lumeng L、Ryan MP、Li TK，“大鼠维生素B6营养中血浆5-磷酸吡哆醛测量的诊断值的验证”，《营养学杂志》，1978年，第108卷，第545-553页)；Li A,Lumeng L,Aronoff GR,Li T-K.Relationship between body store of vitamin B6 and plasma pyridoxal-Pclearance:metabolic balance studies in humans.J Lab Clin Med 1985；106:491-497(Li A、Lumeng L、Aronoff GR、Li TK，“体内维生素B6储备与血浆磷酸吡哆醛清除之间的关系：人体中代谢平衡研究”，《实验室与临床医学杂志》，1985年，第106卷，第491-497页))。虽然有些研究支持30nmol/L的阈值(Leklem JE.Vitamin B-6:a status report.J Nutr1990；120:1503–1507.(Leklem JE，“维生素B6的现状报告”，《营养学杂志》，1990年，第120卷，第1503-1507页))，但要进行有关足量的评估，认为20nmol/L以下的血浆PLP水平才能反映成人中的不良维生素状态(Coburn SP,Lewis DL,Fink WJ,Mahuren JD,SchaltenbrandWE,Costill DL.Human vitamin B6 pools estimated through muscle biopsies.Am JClin Nutr 1988；48:291–294(Coburn SP、Lewis DL、Fink WJ、Mahuren JD、SchaltenbrandWE、Costill DL，“通过肌肉活检评估人类的维生素B6池”，《美国临床营养学杂志》，1988年，第48卷，第291-294页))。有些研究测量了其他B6同效维生素的血浆水平，但这些物质往往比PLP水平波动更大，而且受近期饮食摄入的影响(Contractor SF,Shane B.Estimationof vitamin B6 compounds in human blood and urine.Clin Chim Acta 1968；21:71-77(Contractor SF和Shane B，“人类血液和尿液中维生素B6化合物的评估”，《临床化学学报》，1968年，第21卷，第71-77页))。
对于初始SWS分析，20nmol/L以下的血清PLP水平被用于指示缺乏B6状态。
2)进行统计分析，以揭示SWS中缺乏维生素B6与儿童期肥胖的相关性。
所有SWS儿童的脂肪量变量均呈正偏斜，利用Fisher-Yates正态分数将其转换为平均值为0、标准偏差为1的正态分布变量(Armitage P,Berry G.Statistical methods inmedical research.Oxford,United Kingdom:Blackwell Science Ltd,2002(Armitage P和Berry G，《医学研究的统计方法》，英国牛津Blackwell Science公司，2002年))。以身体组成变量为结果变量，孕产妇微量营养素状态为预测变量，同时考虑可能的影响因素，利用线性回归模型进行拟合。由于儿童身体组成存在性别差异，因此所有的分析均针对儿童性别和儿童年龄进行了调整。利用Stata 11.1(StataCorp.Stata版本11统计软件，德克萨斯州大学城(College Station,TX)：StataCorp LP，2009年)执行统计分析。上文描述了用于微量营养素缺乏/不足的统计分析的阈值。
结果：
血清样品中的PLP和PA结果表明，缺乏维生素B6在南安普敦的妊娠后期孕妇中极为普遍，501个受试对象中就有70.0％的血清PLP水平低于20nmol/L。
怀孕后期缺乏维生素B6与后代4岁和6岁时的较高脂肪量(利用DXA测量)相关。
表1.孕产妇维生素B6状态导致的儿童肥胖。
表1所示的结果对应于用于对图1和图2中所绘测量结果进行统计分析的对数变换值。4岁时的脂肪量百分比分布没有倾斜，因此未进行对数变换。
平均血清维生素B6水平根据生育次数和孕前BMI表现出显著差异(表2)，并且多次生育的母亲和肥胖母亲被鉴定为存在更高的缺乏孕产妇维生素B6的风险(表3)。
表2.根据生育次数和怀孕前BMI的维生素B6状态。
| 平均血清维生素B6(PLP)(nmol/L) | |
| 生育次数 | |
| 初次生育 | 16.8 |
| 多次生育 | 13.5 |
| P值(t检验) | <0.001*** |
| 孕前BMI | |
| <18.5 | 9.8 |
| 18.5-25 | 16.2 |
| 25-30 | 14.2 |
| >30 | 12.5 |
| P值(ANOVA) | 0.01* |
表3.根据生育次数和孕前BMI，维生素B6缺乏风险增加。
这些结果为维生素B6缺乏对后代的肥胖风险具有持久影响这一观点提供了支持，并且为孕前、孕期和哺乳期进行干预以改善孕产妇维生素B6状态提供了强有力的支持。
Claims (15)
1.用于预防母亲的后代发生肥胖、过量脂肪积聚和/或与前述任一种情况相关的代谢紊乱的维生素B6的用途，其中将所述维生素B6在孕前、孕期和/或哺乳期施用于所述母亲。
2.根据权利要求1所述的维生素B6的用途，其中所述维生素B6以孕产妇食物组合物的形式来施用。
3.根据权利要求2所述的维生素B6的用途，其中所述孕产妇食物组合物选自粉状营养组合物、营养配方食品、基于谷类的产品、饮料、食品棒、营养补充剂、营养品、酸奶、乳衍生的产品、食物喷洒物、丸剂或片剂，其中所述粉状营养组合物要在奶或水中重构。
4.根据前述权利要求中任一项所述的维生素B6的用途，其中所述维生素B6以对应于0.19-60mg维生素B6/天、例如1至40mg维生素B6/天的量来施用。
5.根据前述权利要求中任一项所述的维生素B6的用途，其中将所述维生素B6在孕前、孕期和/或哺乳期施用至少4个连续周。
6.根据前述权利要求中任一项所述的维生素B6的用途，其中所述维生素B6以至少每天一次的频率来施用。
7.根据前述权利要求中任一项所述的维生素B6的用途，其中所述维生素B6由天然源提供，所述天然源为例如鱼类；器官肉如牛肝；肉类；蛋类；糙米和小麦；土豆；富含淀粉的蔬菜，如鹰嘴豆、豌豆、豆类、南瓜；水果；干燥的药草和香料；坚果，如开心果和榛子；种子，如葵花籽或芝麻籽；或它们的提取物和/或组合物。
8.根据前述权利要求中任一项所述的维生素B6的用途，其中所述后代在以后生活中的肥胖、过量脂肪积聚和/或与前述任一种情况相关的代谢紊乱得以预防。
9.根据权利要求8所述的维生素B6的用途，其中在所述后代至少3岁、例如至少4岁或至少6岁时肥胖得以预防。
10.根据前述权利要求中任一项所述的维生素B6的用途，其中通过降低脂肪量尤其是腹部和/或内脏的脂肪量来预防肥胖。
11.根据前述权利要求中任一项所述的维生素B6的用途，其中所述母亲是多次生育、超重和/或肥胖的母亲，和/或患有代谢综合征的母亲。
12.孕产妇食物组合物，其中所述孕产妇食物组合物是粉状营养配方食品，所述粉状营养配方食品包含蛋白质源、碳水化合物源、脂质源、卵磷脂、增量剂和0.27-27mg维生素B6/100g干重。
13.根据权利要求12所述的孕产妇食物组合物，还包含益生菌、叶酸、钙、铁、ARA、EPA和/或DHA。
14.维生素B6用于预防母亲的后代超重或具有过量脂肪积聚的用途，其中将所述B6在孕前、孕期和/或哺乳期施用于所述母亲。
15.根据权利要求14所述的维生素B6的用途，其中所述后代在以后生活中的超重得以预防。
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14150798.8 | 2014-01-10 | ||
| EP14150798 | 2014-01-10 | ||
| EP14161188 | 2014-03-21 | ||
| EP14161188.9 | 2014-03-21 | ||
| PCT/EP2015/050358 WO2015104390A1 (en) | 2014-01-10 | 2015-01-09 | Maternal vitamin b6 administration for the prevention of increased adiposity, overweight or obesity in the offspring |
| CN201580003950.2A CN105899208A (zh) | 2014-01-10 | 2015-01-09 | 对孕产妇施用维生素b6 预防后代发胖、超重或肥胖的增加 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580003950.2A Division CN105899208A (zh) | 2014-01-10 | 2015-01-09 | 对孕产妇施用维生素b6 预防后代发胖、超重或肥胖的增加 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115349635A true CN115349635A (zh) | 2022-11-18 |
Family
ID=52347323
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580003950.2A Pending CN105899208A (zh) | 2014-01-10 | 2015-01-09 | 对孕产妇施用维生素b6 预防后代发胖、超重或肥胖的增加 |
| CN202210975211.1A Pending CN115349635A (zh) | 2014-01-10 | 2015-01-09 | 对孕产妇施用维生素b6预防后代发胖、超重或肥胖的增加 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580003950.2A Pending CN105899208A (zh) | 2014-01-10 | 2015-01-09 | 对孕产妇施用维生素b6 预防后代发胖、超重或肥胖的增加 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9980950B2 (zh) |
| EP (1) | EP3091975B1 (zh) |
| CN (2) | CN105899208A (zh) |
| AU (1) | AU2015205514A1 (zh) |
| BR (1) | BR112016014700B1 (zh) |
| CL (1) | CL2016001752A1 (zh) |
| ES (1) | ES2833154T3 (zh) |
| MX (2) | MX2016009039A (zh) |
| PH (1) | PH12016500916A1 (zh) |
| RU (1) | RU2016132884A (zh) |
| WO (1) | WO2015104390A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106551942A (zh) * | 2015-09-28 | 2017-04-05 | 上海中医药大学附属龙华医院 | 一种治疗代谢综合征的药物组合物及其用途 |
| DE102017105377A1 (de) | 2016-03-17 | 2017-09-21 | Jtekt Corporation | Steuerkonsole für Werkzeugmaschinen und Verwaltungssystem für Werkzeugmaschinen |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040213857A1 (en) * | 2003-04-17 | 2004-10-28 | Boehringer Ingelheim International Gmbh | Multi-vitamin and mineral supplement for pregnant women |
| CN1823625A (zh) * | 2006-01-11 | 2006-08-30 | 朱阎宏 | 孕产妇营养食品 |
| CN101472578A (zh) * | 2006-05-23 | 2009-07-01 | 雀巢产品技术援助有限公司 | 孕妇补充剂 |
| US20110311684A1 (en) * | 2010-06-21 | 2011-12-22 | James Rea | Foods and beverages for pregnancy and lactation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1012823B (zh) | 1987-10-31 | 1991-06-12 | 中国科学院广州化学研究所 | 直接蒸馏肉桂叶提取桂油工艺 |
| CN1092953A (zh) * | 1993-03-27 | 1994-10-05 | 杜振文 | 蒲公英保健饮料的生产方法 |
| US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
| KR100645385B1 (ko) | 2005-10-05 | 2006-11-23 | 주식회사 안지오랩 | 비만 억제용 조성물 |
| US7235249B2 (en) | 2002-03-28 | 2007-06-26 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions |
| CA2515407A1 (en) * | 2003-02-10 | 2004-08-26 | Todd Ovokaitys | Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form |
| EP1932437A1 (en) * | 2006-12-15 | 2008-06-18 | Nestec S.A. | Infant formula |
| EP1974734A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
| EP2147678A1 (en) * | 2008-07-21 | 2010-01-27 | Nestec S.A. | Probiotics to increase IgA secretion in infants born by caesarean section |
| US8603555B2 (en) | 2010-04-13 | 2013-12-10 | Mark A. Innocenzi | Methods for quantifying the complete nutritional value of a standard equivalent unit of the nutritional value of one serving of fruits and vegetables (SFV)and for fortifying a base food to contain same for human consumption |
| WO2011150393A2 (en) * | 2010-05-28 | 2011-12-01 | Bmg Hematology Llc | Methods for improving maternal and fetal health |
| CN103478261B (zh) | 2013-08-26 | 2015-04-15 | 黑龙江省乳品工业技术开发中心 | 一种婴幼儿配方奶粉 |
-
2015
- 2015-01-09 WO PCT/EP2015/050358 patent/WO2015104390A1/en active Application Filing
- 2015-01-09 MX MX2016009039A patent/MX2016009039A/es active IP Right Grant
- 2015-01-09 CN CN201580003950.2A patent/CN105899208A/zh active Pending
- 2015-01-09 US US15/109,713 patent/US9980950B2/en active Active
- 2015-01-09 BR BR112016014700-6A patent/BR112016014700B1/pt active IP Right Grant
- 2015-01-09 ES ES15700286T patent/ES2833154T3/es active Active
- 2015-01-09 RU RU2016132884A patent/RU2016132884A/ru not_active Application Discontinuation
- 2015-01-09 CN CN202210975211.1A patent/CN115349635A/zh active Pending
- 2015-01-09 AU AU2015205514A patent/AU2015205514A1/en not_active Abandoned
- 2015-01-09 EP EP15700286.6A patent/EP3091975B1/en active Active
-
2016
- 2016-05-18 PH PH12016500916A patent/PH12016500916A1/en unknown
- 2016-07-08 CL CL2016001752A patent/CL2016001752A1/es unknown
- 2016-07-08 MX MX2019015889A patent/MX2019015889A/es unknown
-
2018
- 2018-01-25 US US15/879,660 patent/US10980786B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040213857A1 (en) * | 2003-04-17 | 2004-10-28 | Boehringer Ingelheim International Gmbh | Multi-vitamin and mineral supplement for pregnant women |
| CN1823625A (zh) * | 2006-01-11 | 2006-08-30 | 朱阎宏 | 孕产妇营养食品 |
| CN101472578A (zh) * | 2006-05-23 | 2009-07-01 | 雀巢产品技术援助有限公司 | 孕妇补充剂 |
| US20110311684A1 (en) * | 2010-06-21 | 2011-12-22 | James Rea | Foods and beverages for pregnancy and lactation |
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016500916A1 (en) | 2016-06-20 |
| RU2016132884A (ru) | 2018-02-14 |
| EP3091975B1 (en) | 2020-08-26 |
| MX2016009039A (es) | 2017-01-16 |
| EP3091975A1 (en) | 2016-11-16 |
| MX2019015889A (es) | 2020-02-07 |
| CN105899208A (zh) | 2016-08-24 |
| US20160324841A1 (en) | 2016-11-10 |
| ES2833154T3 (es) | 2021-06-14 |
| WO2015104390A1 (en) | 2015-07-16 |
| US10980786B2 (en) | 2021-04-20 |
| US20180280369A1 (en) | 2018-10-04 |
| BR112016014700B1 (pt) | 2020-11-10 |
| RU2016132884A3 (zh) | 2018-09-06 |
| US9980950B2 (en) | 2018-05-29 |
| AU2015205514A1 (en) | 2016-07-21 |
| CL2016001752A1 (es) | 2017-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wolfe et al. | Replacement of carbohydrate by protein in conventional-fat diet reduces cholesterol and triglyceride concentrations in healthy normolipidemic subjects | |
| TWI359021B (en) | Nutritional composition for controlling blood suga | |
| US20240122935A1 (en) | Maternal vitamin b2 administration for the prevention of increased adiposity, overweight or obesity in the offspring | |
| JP2022533036A (ja) | 化合物オレウロペイン又はその代謝産物を使用して代謝疲労を治療又は予防する組成物及び方法 | |
| BR112017002176B1 (pt) | Composição para administração materna, seu uso, e kit de partes | |
| JP2013514812A (ja) | 栄養組成物及び食事の酸−塩基のポテンシャルを最適化するための方法 | |
| Rossander et al. | The influence of dietary fibre on mineral absorption and utilisation | |
| US9066915B2 (en) | Meal replacement compositions and weight control method | |
| Freeland-Graves et al. | Nutritional requirements for manganese | |
| EP1972345B1 (en) | Food product for enteral or oral nutrition | |
| Rondanelli et al. | A food pyramid for adult patients with phenylketonuria and a systematic review on the current evidences regarding the optimal dietary treatment of adult patients with PKU | |
| US10980786B2 (en) | Maternal vitamin B6 administration for the prevention of increased adiposity, overweight or obesity in the offspring | |
| CA2953113A1 (en) | Myo-inositol and probiotics, and their use | |
| Banjari et al. | The question is whether intake of folic acid from diet alone during pregnancy is sufficient | |
| US20090137459A1 (en) | Food Product for Enteral or Oral Nutrition | |
| US11065271B2 (en) | Maternal vitamin B12 administration for the prevention of increased adiposity, overweight or obesity in the offspring especially offspring overweight and/or obese mothers | |
| Rastmanesh | An urgent need to include risk–benefit analysis in clinical trials investigating conjugated linoleic acid supplements in cancer patients | |
| de Souza Aquino et al. | Dietary Induction Models of Nutritional Disorders in Rodents: Bases for Translational Studies | |
| El-Qudah et al. | Fat soluble vitamins (A, E and K) intake among a sample of Jordanian university students | |
| KR20160010027A (ko) | 가르시아캄보지아(ｈｃａ)를 유효성분으로 함유하는 체지방 감소를 위한 조성물 | |
| Rees et al. | Diet 14 | |
| Valentine et al. | 19 Nutrition Support |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40084212 Country of ref document: HK |